Independent validation of the 2002 UICC TNM staging system for papillary renal cell carcinoma in a multicenter cohort

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 5092-5092
Author(s):  
C. Wulfing ◽  
E. Herrmann ◽  
L. Trojan ◽  
A. Schrader ◽  
F. Becker ◽  
...  

5092 Background: Papillary renal cell carcinoma (pRCC) is the second most malignant histologic subtype in nephrectomy specimens. To date, the most recognized staging system to stratify renal cancer patients is the 2002 UICC TNM classification system. Its accuracy for predicting patient outcome for pRCC is unknown. Methods: From ten urologic institutions in Germany follow-up data on 675 patients with pRCC were collected. In most cases histologic slides were available and central pathologic review was performed. The Kaplan-Meier method was used to derive the cumulative cancer-specific survival. For multivariate analysis of prognostic factors, a Cox regression analysis was performed. Results: 498 (74.1%) patients had organ-confined tumor stages (≤pT2). Synchronous distant metastases in the entire group occurred in 58 (8.7%) patients and 69 (11.2%) others developed metastatic disease during follow-up. Cancer-specific survival (CSS) was significantly related to TNM stage and histologic grading in univariate as well as in multivariate analysis (all p < 0.0001). 5-year CSS in pT1b tumors (90.0%) was significantly shorter compared to pT1a tumors (98.3%) (p = 0.017). Patients with ≥pT3 were at high risk for metastases (50.6%), while metastatic disease associated with ≤pT2 tumors occurred in 7.8% (p < 0.0001). Once metastatic disease was present, prognosis was poor (5-year CSS: 7.2%). Age was associated with a worse prognosis in the subgroup of ≥pT3 tumors in univariate (p = 0.026), but not in multivariate analysis. Conclusions: The 2002 UICC TNM staging system is applicable for pRCC. Clinical and radiologic follow-ups should be offered in frequent intervals to patients with venous thrombus and/or locally advanced disease. The role of age remains unclear, but should not be underestimated at risk stratification after tumor resection. No significant financial relationships to disclose.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 434-434
Author(s):  
Jasmir Nayak ◽  
Clare Gardiner ◽  
Zhihui Liu ◽  
Simon Tanguay ◽  
Anil Kapoor ◽  
...  

434 Background: A large, multi-institutional analysis was undertaken to examine the pathological and oncological outcomes for patients with pT3 renal cell carcinoma (RCC) treated surgically. Materials and Methods: Institutional databases on patients surgically treated for RCC were obtained from 14 centers across 6 Canadian provinces forming the Canadian Kidney Cancer Information System (CKCis) database. Data were collected on 2204 patients and included patient characteristics, peri-operative information, pathological and oncological outcomes. Results: Of the 2,204 patients, 498 (22.6%) patients had pT3 disease according to the 2009 TNM staging system. Mean pathological tumor size was 8.6 cm. 443 (89.0%) patients underwent a radical nephrectomy (RN) and 55 (11.0%) underwent a partial nephrectomy (PN). Of those treated with RN, 247 (55.8%) were open, 159 (35.9%) laparoscopic and 1 (0.2%) robotic. In the PN group, 37 (67.3%), 14 (25.5%) and 4 (7.3%) patients were treated open, laparoscopic and robotically, respectively. Average operative time was 184 mins, with an average blood loss of 650 cc. Of the pT3 lesions, 365 (73.3%) were pT3a, 97 (19.5%) pT3b and 12 (2.4%) pT3c. 109 (22%) patients had a metastatic diagnosis before or at the time of nephrectomy. Of the remaining 389 patients, 68.9% remained free of disease after a median follow-up of 1.3 years. Common sites of metastatic disease included lung, lymph nodes and bone (77%, 35%, and 25%, respectively). Clear cell RCC was the predominant histopathology (74%). There were no peri-operative (<30 days) mortalities. Complications were found in 14.1% of patients. Systemic therapy was initiated in 132 (26.5%) of patients, most commonly with Sunitinib in 106 (80%) patients. Conclusions: Locally advanced, pT3 renal cell carcinoma is an aggressive disease that is associated with high rates of metastatic disease. Despite this, a significant portion remained disease free at the time of our follow-up.


Cancer ◽  
2005 ◽  
Vol 104 (5) ◽  
pp. 968-974 ◽  
Author(s):  
Vincenzo Ficarra ◽  
Luigi Schips ◽  
François Guillè ◽  
Guorong Li ◽  
Alexandre De La Taille ◽  
...  

2007 ◽  
Vol 51 (3) ◽  
pp. 722-731 ◽  
Author(s):  
Vincenzo Ficarra ◽  
Giacomo Novara ◽  
Massimo Iafrate ◽  
Livio Cappellaro ◽  
Emiliano Bratti ◽  
...  

2011 ◽  
Vol 185 (4S) ◽  
Author(s):  
Juan Ignacio Martinez-Salamanca ◽  
William Huang ◽  
Isabel Millan ◽  
Roberto Bertini ◽  
Fernando Bianco ◽  
...  

2011 ◽  
Vol 59 (1) ◽  
pp. 120-127 ◽  
Author(s):  
Juan I. Martínez-Salamanca ◽  
William C. Huang ◽  
Isabel Millán ◽  
Roberto Bertini ◽  
Fernando J. Bianco ◽  
...  

2020 ◽  
Author(s):  
Jian Zhang ◽  
Xiaoli Li ◽  
Jun Lin ◽  
Zhijia Liu ◽  
Changqing Chen ◽  
...  

Abstract Background The optimal cutoff point for evaluating the prognosis of localized renal cell carcinoma remains unclear. The study aimed to verify the efficacy of tumor diameter in the 2010 AJCC TNM staging system and put forward modification for TNM staging on the prognosis. Methods 3748 patients with localized renal cell carcinoma were enrolled and grouped according to the 2010 AJCC TNM staging system. COX analysis was used to stratify the prognosis and optimal cutoff point of the tumor diameter in the T1 and T2 prognosis was explored. Results 3330 (88.9%) were in stage T1 and 418 (11.1%) were in stage T2. The cancer-specific mortality rate was 2.7% (100/3748). Mean follow-up was 49.8 months. The analysis of tumor diameter at 7 cm can greatly determine the prognosis of patients at stages T1 and T2. However, the tumor diameters of 4.5 and 11 cm set as the cutoff points for T1 and T2 subclassifications of patients with LRCC seemed to have better recognition ability than 4 and 10 cm, respectively. Conclusions The 2010 AJCC TNM stage can greatly predict the prognosis of LRCC in stages T1 and T2. In addition, 4.5 and 11 cm might be optional cutoff points for the tumor diameters for subclassifying stages T1 and T2.


Urology ◽  
2011 ◽  
Vol 78 (3) ◽  
pp. S238
Author(s):  
J. Iizuka ◽  
T. Kondo ◽  
Y. Hashimoto ◽  
H. Kobayashi ◽  
E. Tomita ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document